New drug approvals in 2001.
Wynn
Richard L
RL
Department of Oral-Craniofacial Biological Sciences, Dental School, University of Maryland at Baltimore, USA.
D000279:Administration, Cutaneous; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001862:Bone Resorption / Q000517:prevention & control; D003277:Contraceptives, Oral, Combined / Q000627:therapeutic use; D016861:Cyclooxygenase Inhibitors / Q000627:therapeutic use; D003879:Dermatologic Agents / Q000627:therapeutic use; D004164:Diphosphonates / Q000627:therapeutic use; D017277:Drug Approval; D065128:Endothelin Receptor Antagonists; D065427:Factor Xa Inhibitors; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D006801:Humans; D011505:Protein-Tyrosine Kinases / Q000627:therapeutic use; D017472:Receptors, Interleukin-1 / Q000037:antagonists & inhibitors; D011994:Recombinant Proteins / Q000627:therapeutic use; D014481:United States; D014486:United States Food and Drug Administration
D000894:Anti-Inflammatory Agents, Non-Steroidal; D000970:Antineoplastic Agents; D003277:Contraceptives, Oral, Combined; D016861:Cyclooxygenase Inhibitors; D003879:Dermatologic Agents; D004164:Diphosphonates; D065128:Endothelin Receptor Antagonists; D065427:Factor Xa Inhibitors; D005343:Fibrinolytic Agents; D017472:Receptors, Interleukin-1; D011994:Recombinant Proteins; D011505:Protein-Tyrosine Kinases